FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311753775> ?p ?o ?g. }

• W4311753775 abstract "Abstract Background COVID-19 continues to cause substantial morbidity and mortality globally. It is likely that booster vaccinations will be needed in future years to protect older adults and those with chronic medical conditions. We present interim topline results of a phase 1/2 study of IVX-411 [ACTRN12621000738820.; ACTRN12621000882820], an investigational VLP protein subunit SARS-CoV-2 vaccine, in adults aged 18–69 years (Figure 1). Methods In Part 1, 84 SARS-CoV-2-naïve adults were randomized to receive two doses on Days 0 and 28 of either IVX-411 (5, 25, or 125µg) ± adjuvant, or placebo (Figure 2a). In Part 2, 84 subjects received a single dose of either IVX-411 ± adjuvant or placebo 3–6 months after completion of a primary licensed vaccine regimen (Figure 2b). Solicited adverse events (AEs) were collected for 7 days after each dose, with immunogenicity assessed on Days 0, 28, and 49 [(Part 1) and on Days 0, 7 and 28 (Part 2). Primary outcomes in both parts were solicited and unsolicited AEs, neutralizing antibody titers, and spike protein-specific IgG antibody titers. Results Demographics were similar in the IVX-411 groups vs placebo. In Part 1 and Part 2, local reactogenicity was mild-to-moderate, with higher rates of AEs with increasing doses and addition of adjuvant (Figure 3a). Rates of systemic AEs were similar to placebo across groups (Figure 3b). No vaccine-related severe or serious AEs were noted. IVX-411 was immunogenic in both primary and booster vaccination: in SARS-CoV-2-naïve subjects, a limited dose effect was seen, with significantly higher antibody titers in the groups receiving adjuvanted IVX-411 vaccine (p&lt; 0.01; Figure 4a). The magnitude of antibody responses was similar to, or below, Human Convalescent Sera levels. In previously vaccinated subjects, IVX-411 boosted baseline antibody titers, with no conclusive dose or adjuvant effect (Figure 4b). Immunogenicity was observed across all variants of concern (beta, delta, and omicron) in both parts, with up to 7- fold rises from baseline (Figure 5). Conclusion The study met all primary safety and immunogenicity objectives, with acceptable tolerability profiles in primary and booster vaccination. A clear adjuvant effect was observed in SARS-CoV-2-naïve subjects. Disclosures All Authors: No reported disclosures." @default.
• W4311753775 created "2022-12-28" @default.
• W4311753775 creator A5016817677 @default.
• W4311753775 creator A5032741988 @default.
• W4311753775 creator A5047315777 @default.
• W4311753775 creator A5071043421 @default.
• W4311753775 creator A5081678518 @default.
• W4311753775 date "2022-12-01" @default.
• W4311753775 modified "2023-10-04" @default.
• W4311753775 title "1955. Immunogenicity And Safety of a Virus-Like Particle (VLP) Protein Subunit SARS-CoV-2 Vaccine in Adults: a Phase 1/2 Study" @default.
• W4311753775 doi "https://doi.org/10.1093/ofid/ofac492.1581" @default.
• W4311753775 hasPublicationYear "2022" @default.
• W4311753775 type Work @default.
• W4311753775 citedByCount "0" @default.
• W4311753775 crossrefType "journal-article" @default.
• W4311753775 hasAuthorship W4311753775A5016817677 @default.
• W4311753775 hasAuthorship W4311753775A5032741988 @default.
• W4311753775 hasAuthorship W4311753775A5047315777 @default.
• W4311753775 hasAuthorship W4311753775A5071043421 @default.
• W4311753775 hasAuthorship W4311753775A5081678518 @default.
• W4311753775 hasBestOaLocation W43117537751 @default.
• W4311753775 hasConcept C12590561 @default.
• W4311753775 hasConcept C126322002 @default.
• W4311753775 hasConcept C142724271 @default.
• W4311753775 hasConcept C159654299 @default.
• W4311753775 hasConcept C197934379 @default.
• W4311753775 hasConcept C203014093 @default.
• W4311753775 hasConcept C204787440 @default.
• W4311753775 hasConcept C22070199 @default.
• W4311753775 hasConcept C27081682 @default.
• W4311753775 hasConcept C2777704310 @default.
• W4311753775 hasConcept C2777863537 @default.
• W4311753775 hasConcept C2780868878 @default.
• W4311753775 hasConcept C2781413609 @default.
• W4311753775 hasConcept C32611913 @default.
• W4311753775 hasConcept C535046627 @default.
• W4311753775 hasConcept C61943457 @default.
• W4311753775 hasConcept C71924100 @default.
• W4311753775 hasConceptScore W4311753775C12590561 @default.
• W4311753775 hasConceptScore W4311753775C126322002 @default.
• W4311753775 hasConceptScore W4311753775C142724271 @default.
• W4311753775 hasConceptScore W4311753775C159654299 @default.
• W4311753775 hasConceptScore W4311753775C197934379 @default.
• W4311753775 hasConceptScore W4311753775C203014093 @default.
• W4311753775 hasConceptScore W4311753775C204787440 @default.
• W4311753775 hasConceptScore W4311753775C22070199 @default.
• W4311753775 hasConceptScore W4311753775C27081682 @default.
• W4311753775 hasConceptScore W4311753775C2777704310 @default.
• W4311753775 hasConceptScore W4311753775C2777863537 @default.
• W4311753775 hasConceptScore W4311753775C2780868878 @default.
• W4311753775 hasConceptScore W4311753775C2781413609 @default.
• W4311753775 hasConceptScore W4311753775C32611913 @default.
• W4311753775 hasConceptScore W4311753775C535046627 @default.
• W4311753775 hasConceptScore W4311753775C61943457 @default.
• W4311753775 hasConceptScore W4311753775C71924100 @default.
• W4311753775 hasIssue "Supplement_2" @default.
• W4311753775 hasLocation W43117537751 @default.
• W4311753775 hasOpenAccess W4311753775 @default.
• W4311753775 hasPrimaryLocation W43117537751 @default.
• W4311753775 hasRelatedWork W1964762608 @default.
• W4311753775 hasRelatedWork W2013112188 @default.
• W4311753775 hasRelatedWork W2024103022 @default.
• W4311753775 hasRelatedWork W2145061830 @default.
• W4311753775 hasRelatedWork W2805823297 @default.
• W4311753775 hasRelatedWork W2922130422 @default.
• W4311753775 hasRelatedWork W4225421388 @default.
• W4311753775 hasRelatedWork W4306630473 @default.
• W4311753775 hasRelatedWork W4368362065 @default.
• W4311753775 hasRelatedWork W4379259746 @default.
• W4311753775 hasVolume "9" @default.
• W4311753775 isParatext "false" @default.
• W4311753775 isRetracted "false" @default.
• W4311753775 workType "article" @default.